Keros Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $37 | $83 | $143 | $8 |
Gross Profit | -269 | -194 | -104 | -543 |
EBITDA | -50,133 | -48,483 | -39,996 | -43,280 |
EBIT | -50,439 | -48,760 | -40,243 | -43,831 |
Net Income | -45,257 | -43,114 | -40,243 | -39,440 |
Net Change In Cash | 37 | 83 | 143 | 8 |
Free Cash Flow | -40,111 | -45,506 | -26,000 | -34,532 |
Cash | 405,863 | 442,443 | 331,147 | 287,893 |
Basic Shares | 36,103 | 29,447 | 30,126 | 29,668 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $151 | $20,000 | $20,100 | $2,500 |
Gross Profit | -664 | -1,615 | 19,202 | -605 |
EBITDA | -166,932 | -104,678 | -56,729 | -45,527 |
EBIT | -167,747 | -106,293 | -57,627 | -46,132 |
Net Income | -152,992 | -104,680 | -58,744 | -45,361 |
Net Change In Cash | 151 | 20,000 | 20,100 | 2,500 |
Cost of Revenue | 49,006 | -34,622 | 258,856 | |
Free Cash Flow | -126,972 | -71,303 | -63,172 | -37,188 |
Cash | 331,147 | 279,048 | 230,042 | 265,876 |
Basic Shares | 29,447 | 25,241 | 23,333 | 15,506 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$1.25 |
2024-03-31 | -$1.21 |
2023-12-31 | -$1.34 |
2023-09-30 | -$1.33 |
